RENK better than HENSOLDT? Risk at NOVO NORDISK! Billion-dollar opportunity with RZOLV Technologies!?

RZOLV Technologies: Billion-dollar market in sight

Gold is currently shining brighter than ever. The price per troy ounce is solidly above USD 4,000. Despite all the euphoria, however, the extraction of the precious metal remains a dirty business. Take sodium cyanide, for example: this highly toxic chemical is used in over 90% of global production, as it can efficiently leach very finely distributed gold from low-grade ores. However, due to the health risks, there is growing public resistance in gold-producing regions, even leading to a complete ban in some cases. As a result, there is considerable pressure on industry to find an alternative. Whoever offers this alternative could earn billions. This is precisely the goal of RZOLV Technologies.

For years, the Canadian company has been researching a safe alternative to sodium cyanide. And it seems to be on the home stretch. RZOLV has developed a water-based, non-toxic leaching formulation. The process is patent pending. The renowned testing service provider SGS and other external tests have confirmed that the solution is on par with cyanide in terms of yield and speed. Another important factor for gold companies is that the RZOLV product can be used in existing plants. Mine operators, therefore, do not need to purchase new equipment or machinery, but simply replace the sodium cyanide.

The potential for the RZOLV invention is huge, with the volume of the cyanide market estimated at USD 2.5 billion. In addition, new mines or old tailings piles can be developed in regions where cyanide is banned.

The next step is to conduct a 100-ton pilot test in Arizona. The Company has already raised CAD 2.85 million for this purpose. A dilutive capital increase is therefore not currently expected. If the pilot is successful, the cyanide alternative will go into mass production or be licensed out. A complete takeover by a chemical company also seems plausible. Given the potential, it might appear tempting to add a few RZOLV shares to one's portfolio at the current price of around EUR 0.29. RZOLV Technologies' shares have been listed on the TSX Venture Exchange in Canada since October 2025. They are now also listed in Germany.

RENK shares better than Hensoldt?

Is RENK staging a comeback rally? Last week, the share price rose by over 7% and is now trading above EUR 50 again. It is still a long way off its October high of EUR 90, but the bottom may have been reached.

Bank of America currently sees a buying opportunity in RENK. The recommendation has been upgraded from "Underperform" to "Buy." Analysts recently raised their price target from EUR 56.50 to EUR 60.50. Analysts consider the transmission specialist's long-term goal of achieving an EBIT margin of around 21.5% on revenue of around EUR 3 billion to be feasible. The experts have raised their EBIT estimates for the coming years slightly.

However, analysts are not so optimistic about all German defense stocks. Hensoldt was downgraded from "Buy" to "Neutral." Analysts have slashed their price target for Hensoldt shares from EUR 114 to EUR 77. The sensor specialist's stock is currently trading at around EUR 69. Experts believe that Hensoldt is having problems converting its order backlog into revenue growth. This is likely to change only slowly. Therefore, the valuation level is already ambitious.

Novo Nordisk: Is the stock cheap or expensive?

Novo Nordisk's stock is not currently valued ambitiously. However, after several profit warnings in the current year, it is at least reasonable to question whether the forecasts for the coming years will be met. At EUR 41, the share price is not far from its low for the year, but would have to more than double to reach its high for the year.

Filling the drug pipeline through acquisitions is risky. Pfizer has tried this in recent years and suffered several flops. Ironically, it was Pfizer that Metseras fought a bidding war with and lost.

Instead, Novo Nordisk struck a deal with Akero Therapeutics. The shareholders of the US biotech company approved the takeover a few days ago. Including possible milestone payments, the acquisition will cost Novo Nordisk up to USD 5.2 billion. Akero's drug candidate Efruxifermin for the treatment of liver disease is in late-stage clinical development, but could still fail.

The Danish company has also suffered another setback in its own research recently. There had been hope that Novo Nordisk's diabetes drug semaglutide would not only help with weight loss but could also be used to treat early-stage Alzheimer's disease. After two years of research, the project has now been discontinued. Two extensive studies with 3,800 participants had yielded insufficient results.

Developments at RZOLV Technologies are extremely exciting. If the product delivers what it promises, the stock has enormous potential. Adding it to your portfolio could pay off as early as 2026. The RENK share appears to have bottomed out for the time being. Are the earnings estimates for Novo Nordisk realistic for the coming years? If so, the share would currently be cheap. However, the share price shows that the market currently has serious doubts.